Number of pages: 100 | Report Format: PDF | Published date: May 29, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
Report Attribute |
Details |
CAGR |
12.3% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Type, Indication, Distribution Channel, End User, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global sympathomimetic drugs market is expected to register a revenue CAGR of 12.3% during the forecast period.
Sympathomimetic Drugs Market Fundamentals
The effects of endogenous catecholamines, such as norepinephrine and epinephrine, are mimicked by drugs known as sympathomimetics. Due to this, these drugs stimulate the sympathetic nervous system, which in turn sets off the fight-or-flight response, raising blood pressure and heart rate and delaying digestion. Blood flow to the muscles and brain is increased due to this reaction.
Dobutamine, dopamine, norepinephrine, epinephrine, and isoproterenol are now among the pharmaceuticals known as sympathomimetic drugs. All of them are delivered intravenously; however, isoproterenol and epinephrine may also be given intramuscularly, by endotracheal tube, or via inhalation. Once taken, these drugs activate adrenergic receptors alpha and beta subtypes. Vasoconstriction happens when alpha-adrenergic receptors are stimulated, whereas beta-1 adrenergic receptor activation increases heart rate and contractility, and beta-2 adrenergic receptor stimulation produces vasodilation and bronchodilation.
Arrhythmias, cardiovascular hypertension, and gastrointestinal problems are some of sympathomimetics' frequent adverse effects. Monitoring hemodynamic state, adjusting dosages as necessary, monitoring for side effects, and determining if the target therapeutic response has been achieved are all nursing considerations for patients taking sympathomimetics.
Sympathomimetic Drugs Market Dynamics
An increase in the incidence and prevalence of asthma and COPD, cardiovascular diseases, cutting-edge therapeutic drugs, and a rising elderly population are some of the reasons fueling the market's expansion. For instance, chronic obstructive pulmonary disease (COPD) is a common, preventable, and curable chronic lung illness affecting both men and women worldwide is chronic obstructive pulmonary disease (COPD). The anticipated pooled prevalence of COPD in South Asian nations in 2021 was 11.1%, according to an NCBI report published in March 2022. According to the survey, Bangladesh (13.5%) and North India (19.4%) had the highest rates of COPD prevalence.
Additionally, the market is growing due to the rising global elderly population. For instance, one in six people worldwide will be 60 years of age or older by the year 2030. There will be 1.4 billion people, up from 1 billion in 2020, who are 60 years of age or older. The number of individuals 60 and older globally will double (to 2.1 billion) by the year 2050. Between 2020 and 2050, there will be 426 million more people who are 80 years of age or older than there are now.
The market participants use various techniques to grow their market shares, including new launches, innovations, partnerships, acquisitions, and expansions. For instance, in October 2021, premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine) was approved by the U.S. Food and Drug Administration (FDA) and has been made commercially available by Baxter International Inc., a world leader in the development and distribution of sterile medications. When an adult patient has severe, acute hypotension (low blood pressure), norepinephrine is prescribed to increase blood pressure.
However, drug shortage is the main restraining factor in the market; for instance, the FDA announced a shortage of the immediate-release version of amphetamine mixed salts, often known as Adderall or Adderall IR, on the medication shortage website in October 2022. All producers of amphetamine mixed salts are in regular contact with the FDA, and one of them, Teva, is dealing with continuous intermittent manufacturing delays. Although there is still a need for amphetamine mixed salts in the U.S. market, there is not enough supply for other manufacturers to keep up with production.
Sympathomimetic Drugs Market Ecosystem
The global sympathomimetic drugs market is analyzed from the following perspective by type, indication, distribution channel, end user, and region.
Sympathomimetic Drugs Market by Type
Based on the types, the global sympathomimetic drugs market is segmented into direct sympathomimetics, indirect sympathomimetics and mixed sympathomimetics.
Mixed sympathomimetics has the highest proportion of the global sympathomimetics market share. Mixed sympathomimetics have both direct and indirect effects on the adrenergic receptors, leading to a more potent and long-lasting effect compared to direct or indirect sympathomimetics alone. This unique characteristic has made mixed sympathomimetics popular and in high demand for the treatment of certain conditions.
One reason for the high demand for mixed sympathomimetics is their ability to treat asthma. Asthma is a chronic condition affecting the airways and breathing. Mixed sympathomimetics such as ephedrine can stimulate the adrenergic receptors directly and increase the release of norepinephrine, which can help dilate the airways and improve breathing. Growing asthma and COPD prevalence worldwide is a key factor supporting the high demand for mixed sympathomimetic drugs globally. As per the Asthma and Allergy Foundation of America, at present, about 4.8 million under 18 children are living with asthma. The WHO reported that in 2019, asthma affected 262 million individuals, and caused 445,000 deaths.
Mixed sympathomimetics are also used to treat low blood pressure. Mixed sympathomimetics such as ephedrine can increase blood pressure by constricting blood vessels and stimulating the heart. Furthermore, mixed sympathomimetics are used in the treatment of attention deficit hyperactivity disorder (ADHD). ADHD is a neurodevelopmental disorder that affects a person's ability to focus and control impulses. Mixed sympathomimetics such as ephedrine and pseudoephedrine can increase the levels of norepinephrine and dopamine in the brain, which can improve focus and attention.
Sympathomimetic Drugs Market by Indication
Based on the indication, the global sympathomimetic drugs market is segmented into cardiovascular disease, asthma & COPD, glaucoma, and others.
Asthma and COPD, and cardiovascular diseases have the highest uptake of sympathomimetic drugs, worldwide. High prevalence of these conditions are mainly attributed to the dominance of these segments. The World Health Organization estimates that 339 million people worldwide have asthma, and that number will likely increase to 400 million by 2025. The fact that sympathomimetics are among the most frequently prescribed medications for asthma is not surprising given the condition's high prevalence. Cardiovascular diseases are the leading cause of death worldwide, accounting for 17.9 million deaths in 2019 alone. According to the American Heart Association, over 100 million Americans have some form of cardiovascular disease. Therefore, the use of sympathomimetics in managing these conditions is critical in preventing complications and improving outcomes.
Sympathomimetic Drugs Market by Distribution Channel
Based on the distribution channels, the global sympathomimetic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies are predicted to hold the majority of the market share due to the fact that these medications are frequently administered following an in-depth diagnosis, which is frequently carried out at these institutions.
The retail pharmacies segment would have the second-largest share because these pharmacies may offer more effective facilities for re-filling prescriptions. Due to the rising utilization of online pharmacy services, which are becoming increasingly popular because of their simplicity and convenience, the category of online pharmacies is predicted to enjoy the greatest CAGR for revenue growth.
Sympathomimetic Drugs Market by Region
Based on the region, the global sympathomimetic drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America showed its dominance during the forecast period. The high incidence of cardiovascular illnesses, asthma & COPD, and glaucoma, together with new product releases across the region, will propel the market expansion for sympathomimetic drugs in the region. In addition, the market in North America is anticipated to grow rapidly due to rising research and development activities, rising awareness, and the prevalence of risk factors like diabetes in the general population. For instance, a cardiovascular event happens in the US every 40 seconds, and over 805,000 Americans have a heart attack yearly, according to the CDC's latest data published in October 2022. The need for cardiovascular treatment will thus rise in future years as the burden of sympathomimetic drugs grows.
The market for sympathomimetic drugs is expected to grow as a result of factors such as rising new product development, rising patient population, rising adrenergic drug applications for a range of disease indications, technological advancements, rising incidence of chronic diseases, rising public awareness of the importance of early diagnosis, rising strategic partnerships, and rising product approvals by regulatory bodies. For instance, in September 2020, the US FDA authorized Zydus Cadila to commercialize Midodrine Hydrochloride tablets. For certain people, who have symptoms of low blood pressure when standing, the medication is utilized. Orthostatic hypotension is another name for this disorder. The group's formulation manufacturing plant in SEZ, Ahmedabad, will produce the medication.
Asia Pacific is known for its large population, rising cardiovascular disease prevalence, rising healthcare spending, and rising government investments in the development of sophisticated healthcare infrastructure, all of which are anticipated to fuel the expansion of the sympathomimetic drugs market in the region. According to the World Health Organization, around 75% of fatalities from cardiovascular illnesses occur in low- and middle-income nations. Growing affordability and accessibility to healthcare services are encouraging the use of sympathomimetic drugs.
Sympathomimetic Drugs Market Competitive Landscape
Some of the prominent market players in the global sympathomimetic drugs market include,
Sympathomimetic Drugs Market Strategic Development
The effects of endogenous catecholamines, such as norepinephrine and epinephrine, are mimicked by drugs known as sympathomimetics. Due to this, these drugs stimulate the sympathetic nervous system, which in turn sets off the fight-or-flight response, raising blood pressure and heart rate and delaying digestion.
The North America region is dominating the global sympathomimetic drugs market in 2022.
The revenue CAGR of sympathomimetic drugs market during the forecast period will be 12.3%.
Some of the prominent market players in the global sympathomimetic drugs market include Teva Pharmaceutical Industries Ltd., Baxter International Inc., Mallinckrodt, Inc.
The mixed sympathomimetic drugs segment leads the global market in 2022.
*Insights on financial performance are subject to the availability of information in the public domain